Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Side effect and safety data for fenbufen.

R J Crossley

    The American Journal of Medicine
    |October 31, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), demonstrates a favorable safety profile. It shows reduced gastrointestinal side effects compared to aspirin and indomethacin, with similar safety to placebo.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes.

    Lancet (London, England)·1990
    Same author

    Clinical safety and tolerance of mitoxantrone.

    Seminars in oncology·1984
    Same author

    Clinical safety and tolerance of mitoxantrone (Novantrone).

    Cancer treatment reviews·1983
    Same author

    Project planning, investigator selection, data harmonization.

    Drug information journal·1981
    Same author

    Cimetidine in the treatment of duodenal ulcer: a multicenter double blind study.

    Gastroenterology·1978
    Same author

    Cimetidine, antacid, and hospitalization in the treatment of benign gastric ulcer: a multicenter double blind study.

    Gastroenterology·1978
    Same journal

    GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

    The American journal of medicine·2026
    Same journal

    Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

    The American journal of medicine·2026
    Same journal

    Cave Canem - Beware of the Dog.

    The American journal of medicine·2026
    Same journal

    Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

    The American journal of medicine·2026
    Same journal

    Mesenteric Panniculitis.

    The American journal of medicine·2026
    Same journal

    Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

    The American journal of medicine·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Clinical Medicine
    • Drug Safety Evaluation

    Background:

    • Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
    • Gastrointestinal (GI) adverse events are a common concern with NSAID therapy.
    • Fenbufen is an NSAID requiring comprehensive safety assessment.

    Purpose of the Study:

    • To evaluate the overall safety and tolerability of fenbufen in a large patient population.
    • To compare the safety profile of fenbufen against aspirin, indomethacin, and placebo.
    • To analyze adverse events, including gastrointestinal and cutaneous disorders, and laboratory parameter changes.

    Main Methods:

    • Safety data collected from 2,667 patients in domestic and foreign clinical studies.
    • Comparative analysis with aspirin, indomethacin, and placebo groups.

    Related Experiment Videos

  • Life-table analysis for gastrointestinal reaction incidence and severity.
  • Evaluation of clinical laboratory results for fenbufen-treated patients.

    • Main Results:

    • Fenbufen exhibited a relatively safe NSAID profile with fewer GI adverse events than aspirin or indomethacin.
    • GI reactions with fenbufen were similar to placebo during the initial three months of therapy.
    • Cutaneous disorders were transiently higher in the first month compared to placebo.
    • Occasional, reversible elevations in alkaline phosphatase and transaminase levels were noted, without drug-related jaundice.

    Conclusions:

    • Fenbufen is well-tolerated and offers a good therapeutic ratio, especially concerning GI intolerance.
    • Its safety profile supports its use as an anti-inflammatory agent.
    • Fenbufen presents a favorable alternative for patients sensitive to NSAID-induced GI effects.